• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » MassDevice.com Q&A: James Mazzo on his move to Versant Ventures

MassDevice.com Q&A: James Mazzo on his move to Versant Ventures

July 30, 2013 By Brad Perriello

MassDevice.com Q&A: James Mazzo on his move to Versant Ventures

James Mazzo has put 35 years into the optics and ophthalmology business, so it was no surprise that he got involved with AcuFocus and its device for treating presbyopia. Mazzo, who stepped down from leading Abbott Medical Optics earlier this year, added another title to his resume that’s more of a departure: He’s the 1st "operating partner" at Versant Ventures.

The Menlo Park, Calif.-based venture capital shop tapped Mazzo for chairman & CEO of AcuFocus and its Kamra inlay. But it’s the OP role, which will see Mazzo apply his operational chops across Versant’s medtech portfolio, that’s the departure for the medtech vet.

Mazzo told MassDevice.com last week that he wanted to stretch himself following nearly a decade at the helm of Advanced Medical Optics (later Abbott Medical Optics after a $2.8 billion acquisition). The move to Versant in May came about after Mazzo was almost certain he’d like to try the private equity world, he told us.

Sign up to get our free newsletters delivered straight to your inbox

"When I finally said, ‘I’m going to retire from AMO,’ and announced that at the beginning of last year, I started looking around for various next moves," Mazzo said. "As the year progressed and moved into 2013, I really narrowed it down almost exclusively to entering private equity world."

But through his work with AcuFocus, Mazzo got to know the Versant team better, and when managing director William Link broached the operating partner role, he took the plunge.

"Versant has a wide portfolio outside of ophthalmology, which appeals to me, because I wanted to do something different, to look at other areas outside of ophthalmology. Versant allows me to look at opportunities that are not just in ophthalmology," Mazzo said.

Read on for a transcript of our chat, edited for clarity, in which Mazzo explains his new role at Versant, his decision to guide AcuFocus and what he’s excited about in eye care.

MassDevice.com: Tell us about your new role at Versant.

James Mazzo: I’m the only operating partner, so the good news is there’s only 1 of me, and I’m the 1st one. The operating partner is a partner who looks at the current assets of an entity, in this case Versant Ventures, and is responsible for overseeing the various assets to ensure they are in strong operational function. So my job is to look at all of our assets across Versant and then bringing my expertise of operational excellence, insuring the companies are doing well.

The other investment professionals are constantly out there foraging. They’re hunters. They’re looking for assets, they’re looking to invest in assets. My responsibility is more to lead and manage existing assets, with a special focus on a couple at a time. I will also be helping, because of my experience in the medical device arena, looking for assets as well – if I see something, I would bring it to the Versant team.

What I loved about Versant is that it’s not just in the ophthalmic area. I’ve had experience in dermatology, aesthetics, and to some extent cardiovascular and being with other entities and watching and being the chair of AdvaMed. Versant has a wide portfolio outside of ophthalmology, which appeals to me, because I wanted to do something different, to look at other areas outside of ophthalmology. Versant allows me to look at opportunities that are not just in ophthalmology.

It’s a great group of investment and financial partners, but they haven’t had an operating partner. So being the 1st in a leading venture capital group was something that was really appealing to me. I can learn from them and what they’ve done in the past, and hopefully I can bring some discipline to running companies, because obviously that’s what I’ve done in the past. We spun AMO, we sold Abbott, we acquired 6 assets while at AMO and 2 while at Abbott. These are the kinds of things I like to do. The combination of being a great company, great science at Versant, and being able to be the 1st operating partner was very exciting to me.

MassDevice.com: What other options did you consider before you decided to join Versant?

James Mazzo: I was with Allergan for 22 years, lived overseas, ran Europe, Africa and the Middle East, then took AMO public when we spun from Allergan in 2002 and sold it to Abbott. Upon the acquisition with Abbott, I had agreed to stay in my role of running AMO for a couple of years and then transfer it over to a new leader. During that time, I also became chairman of AdvaMed, so that extended me to a 3rd year with Abbott, because I wanted to continue in that role as chairman.

Last year I had a conversation with the senior management at Abbott and said, "OK, I think it’s time for me to move on and you put on a new leader at AMO, per what we had discussed earlier when we sold the company." I agreed to stay on and help with that transition for about a year as we identified the candidate, Murthy [Simhambhatla], and then Murthy came on and he mirrored me until the end of the year, and then I worked with him until the end of May. So I retired from Abbott at the end of May

When I finally said, "I’m going to retire from AMO," and announced that at the beginning of last year, I started looking around for various next moves. Do I go back into the public world and become a public CEO? Do I go back to being the CEO of a private entity? I looked at private equity, I looked at venture capital and I really spent a long time analyzing it. It was a great time for me to continue to run AMO and listen, learn in areas I knew and listen, learn in areas I didn’t know. As the year progressed and moved into 2013, I really narrowed it down almost exclusively to entering private equity world. I had done CEO of a public company, CEO of a private company – that’s a little different, but not that much different, so I really wanted to stretch myself into doing something I had never done before.

At that time Bill Link, who is one of the managing partners at Versant, asked if I would be willing to be executive chair of AcuFocus, which I agreed to at the beginning of the year. As I spent more time with the Versant people and really identified what I like to do and what I do well, Bill and the Versant people said, "Look, why don’t you look at what you were looking at in the private equity world where you could help run assets, but do it with Versant and become our 1st operating partner, where you can control all assets but with a special focus on several assets at a time."

I decided to do it is because I enjoy putting operational controls and organizing entities and making them stronger, I like putting management teams in place and identifying strong people, I like putting organizations in place to potentially move on and grow and be sold or acquired per se. So it was a good combination and I also knew the people at Versant well so I decided to pursue that by becoming their first operating partner.

MassDevice.com: Do you think Versant will look to add on another operating partner? Will this be something that catches on at other VC shops?

James Mazzo: Well, you hope you’re successful enough that it leads to others. Hopefully I execute to the level that I promised to do and if so, it catches on not only with Versant, but with other venture groups., When you have assets, those assets can always use some discipline to make them better assets. And even if they’re great assets, there’s no reason they can’t be greater. Nobody ever stops learning or stops growing, so if you can bring great assets together and harmonize around some disciplines, which hopefully I’ve had with my 30-odd years of experience. I would hope that it would grow into other operating partners and that other venture firms will look at it.

MassDevice.com: What’s most exciting to you now, as you survey the optics and ophthalmology field?

James Mazzo: I love this industry. I’ve been in it 33 years so it’s in my blood. So it doesn’t take much to get me excited about optometry or ophthalmology in any way, because it’s something I’ve known and grown up with and I know everyone in the field.

But I would say the primary focuses of interest would be retina, it would be glaucoma, because those are 2 areas where we don’t have a cure for a terrible disease that leads to blindness. Another area is dry eye. It’s been an area of passion for a long time. It goes back even to the days when Gavin Herbert brought me on board, because it’s a disease that is misdiagnosed and even goes undiagnosed and it affects a tremendous amount of people. It has various stages and we really don’t have very strong products or systems to be able to meet this ongoing need on a global basis.

And then presbyopia – it’s not a disease entity like we think of in glaucoma or retina, but it is debilitating from a standpoint of being able to see in the fashion that we all want. Yes, we can have Lasik and put a presbyopic eye well in or a camera product that we have here at AcuFocus, but still presbyopia is a disease that’s only going to grow in prevalence as we all get older.

MassDevice.com: What was it about AcuFocus that made you want to join the company?

James Mazzo: That kind of goes back to what I said about private companies and why I wanted to join a company. It’s got great science. It hits an age group that’s post-Lasik, pre-cataract, so there really isn’t a treatment other than glasses. So it was the ability to impact a population that has a need but doesn’t have opportunities.

The company is in great shape, but it just needed some leadership directions and controls and added people. So it had a lot of the essence of what I was talking about, the operational excellence that I like to do and get involved in. So it moved from a science project to an actual company on a global basis. It’s in the midst of moving toward FDA approval, so there’s a lot of excitement around that. So it had a lot of interest for me and it’s obviously in a space I know quite well, so I agreed to take it on as executive chair and now as operating partner. This 1 was just a natural progression for me to take on, to spend more time helping this great management team lead it to the next level.

MassDevice.com: Where is AcuFocus now on the regulatory pathway?

James Mazzo: We have filed [for pre-market approval] and are currently in discussions with the FDA as we speak, hoping we’ll get to [an FDA advisory] panel sometime next year. We are well on schedule and very excited about it.

We’re approved and selling in Japan, we’re approved in many countries across the globe. We just got approval in Canada and Mexico, so we have a very strong global footprint, but obviously the U.S. is a critical phase for this company and takes it obviously to the next level.

Filed Under: News Well, Optical/Ophthalmic Tagged With: Abbott, AcuFocus Inc., AdvaMed, Advanced Medical Optics, MassDevice Q&A, Venture Capital/Private Equity, Versant Ventures

In case you missed it

  • Calyxo raises $32.7M for kidney stone treatment
  • Getinge anesthesia systems recall is Class I
  • RefleXion closes $125M debt facility
  • Senseonics announces equity grants to employees
  • New data backs Aerin’s RhinAer for treating chronic rhinitis
  • Enovis completes Insight Medical acquisition
  • Orchestra BioMed to go public, partner with Medtronic on cardiac neuromodulation therapy
  • Memic Innovative Surgery is now Momentis Surgical
  • Lyra Therapeutics appoints new chief medical officer
  • Masimo’s SafetyNet monitoring reduced length of COVID-19 hospital stays, study says
  • CeQur is launching a discreet, convenient ‘wearable insulin pen’
  • Teva appoints former Vertex exec as new head of R&D, CMO
  • Enovis partners with Kelvi on hot and cold therapies
  • West Pharmaceutical Services debuts new needle syringe system
  • Titan Medical names Cary G. Vance as new president, CEO
  • Acutus completes first closing in left-heart access portfolio sale to Medtronic
  • FDA clears Intuitive, Siemens Healthineers imaging integration for robotic bronchoscopy

RSS From Medical Design & Outsourcing

  • FDA can’t explain drop in device recalls, but experts point to COVID disruptions
    The FDA acknowledged interruptions with notifications from recalling firms during the pandemic, while regulatory experts point to fewer inspections and fewer procedures. FDA medical device product recalls dropped last year to their lowest level since 2013, according to a Medical Design & Outsourcing analysis of recall data from the regulatory agency. Medtech regulatory experts said the COVID-19… […]
  • DeviceTalks Boston 2022: Here’s what you missed on the show floor
    At DeviceTalks Boston 2022, there was a wealth of expertise to be had from exhibitors including Viant, ICS, PSN Labs, Propel and more. From stories of overcoming challenges during the COVID-19 pandemic to medical device materials pitfalls to avoid, MassDevice and MDO executive editor Chris Newmarker hit the DeviceTalks Boston show floor to discover insights. […]
  • Supply Chain EVP Greg Smith sees fewer suppliers in Medtronic’s future
    All eyes are on Medtronic’s global operations and supply chain leader as he works to modernize its operations and scrutinize suppliers. EVP of Global Operations and Supply Chain Greg Smith anticipates fewer suppliers in Medtronic’s future, he said in an interview this week. Smith spoke with DeviceTalks Editorial Director Tom Salemi in his first published… […]
  • CeQur is launching a discreet, convenient ‘wearable insulin pen’
    CeQur designed its Simplicity device to make insulin delivery as seamless as possible for people with diabetes. When it comes to managing diabetes, CeQur wants to make insulin therapy as convenient as possible. For those who prefer to manage their own insulin delivery, the Simplicity device might just do exactly that. Simplicity, a wearable, disposable… […]
  • Meddux opens new facility in Colorado
    Engineering, design, development and manufacturing company Meddux announced that it opened a new facility in Boulder, Colorado. The new, 22,000-square-foot facility doubles the overall square footage from its previous location in Colorado. According to a news release, it helps the company to quadruple its product development area and double its manufacturing footprint. Meddux’s new facility… […]
  • Reducing the Overall Cost of Validation
    By PTI Engineered Plastics Reliable medical devices and equipment are essential for researchers and doctors to accurately diagnose and treat a wide range of diseases. That is why there is such stringent oversight from the FDA to ensure these products meet the necessary requirements and specifications. To ensure compliance with regulators, manufacturers follow installation qualification… […]
  • BBS Automation has a deal to buy medtech supplier Kahle Automation
    BBS Automation said it plans to purchase high-speed automation supplier Kahle Automation to expand its medtech and life sciences business. Kahle will operate as Kahle – a BBS Company, according to a news release from Munich, Germany-based BBS and Lombardy, Italy-based Kahle. The deal is subject to regulatory approval. Terms were not disclosed. Kahle’s co-owners —… […]
  • How safe is health information after the overturning of Roe?
    The U.S. Department of Health and Human Services today issued guidance meant to better protect women’s health information as state abortion bans kick in after the U.S. Supreme Court’s overturning of Roe v. Wade. Despite the HHS actions, women may still wonder whether their health information is entirely safe going forward — a potential challenge… […]
  • Dexcom focuses on early diabetes diagnosis as COVID links emerge
    New evidence is showing that COVID-19 may increase a person’s risk of diabetes, but it could be years until we know for sure. In the meantime, Dexcom (Nasdaq:DXCM) is getting ready, VP of Global Clinical Initiatives Tomas Walker said. Walker recently spoke with Medical Design & Outsourcing to discuss the San Diego-based diabetes device developer’s… […]
  • Blackrock Neurotech and Pitt work on first at-home BCI system for remote trials
    Blackrock Neurotech and the University of Pittsburgh’s Rehab Neural Engineering Labs (Pitt RNEL) are working together on the first portable brain-computer interface (BCI) to allow patients to participate in research trials from home. A Blackrock representative said it’s the final step as the company prepares to launch its first commercial product early next year. Salt… […]
  • How medical device companies are responding to abortion bans
    Days after the U.S. Supreme Court’s decision to overturn Roe v. Wade’s protection of abortion rights, medical device companies are among those reassuring workers about healthcare access. Corporate communications to employees and the public at large come as trigger laws in nearly half of the states outlaw abortion immediately. Some medtech companies are not using… […]

Leave a Reply

You must be logged in to post a comment.

Primary Sidebar

DeviceTalks Weekly

July 1, 2022
Boston Scientific CEO Mike Mahoney on building a corporate culture that drives high growth results
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS